Your browser doesn't support javascript.
loading
Penicillin Allergy Delabeling Program: an exploratory economic evaluation in the Australian context.
Brusco, Natasha K; Bury, Susan; Chua, Kyra Y L; Vogrin, Sara; Holmes, Natasha E; Trubiano, Jason A.
Afiliação
  • Brusco NK; Health Economics, Alpha Crucis Group, Melbourne, Victoria, Australia.
  • Bury S; Rehabilitation, Ageing and Independent Living (RAIL) Research Centre, Monash University, Melbourne, Victoria, Australia.
  • Chua KYL; Department of Infectious Diseases, Austin Health, Melbourne, Victoria, Australia.
  • Vogrin S; Department of Pharmacy, Austin Health, Melbourne, Victoria, Australia.
  • Holmes NE; Department of Infectious Diseases, Austin Health, Melbourne, Victoria, Australia.
  • Trubiano JA; Department of Medicine (St Vincent's Hospital), University of Melbourne, Melbourne, Victoria, Australia.
Intern Med J ; 53(1): 74-83, 2023 01.
Article em En | MEDLINE | ID: mdl-34523209
BACKGROUND: Internationally, clinical and economic advantages of low-risk penicillin delabelling have been explored, supporting changes to healthcare delivery systems where penicillin delabelling is embedded into inpatient usual care. AIMS: To determine if economic advantages of low-risk inpatient penicillin delabelling, described in the international literature, are realised in the Australian context. METHODS: This explorative economic evaluation had prospective patient data collection between January and August 2019, across two Australian health services. Part 1: determine the cost per effectively delabelled patient for Penicillin Allergy Delabeling Program inpatients (PADP cohort) compared with Outpatient Antibiotic Allergy Testing Service outpatients (OAATS cohort). Part 2: a cost analysis to compare hospital costs for inpatients with low-risk penicillin allergy who did (PADP cohort) and did not (usual care cohort) undergo PADP delabelling. RESULTS: Part 1: the PADP (n = 350) and OAATS (n = 27 patients, n = 36 individual visits) cohorts were comparable. In PADP, costs/proportion delabelled was $20.10/0.98, equating to $20.51 per effectively delabelled patient; in OAATS, it was $181.24/0.50, equating to $362. Compared with OAATS, PADP was associated with savings of $341.97 per effectively delabelled patient, indicating the outpatient testing was the dominated strategy, being more costly and less effective. Part 2: the PADP (n = 218) and usual care (n = 32) cohorts were comparable. Significantly favouring the delabelled PADP cohort, the mean difference per patient was -4.41 days (95% confidence interval: -7.64, -1.18) and -$9467.72 (95% confidence interval: -$15 419.98, -$3515.46). CONCLUSIONS: Consistent with international literature, delabelling low-risk penicillin allergies in the inpatient setting had economic advantages in the Australian context. Fully powered economic evaluations are urgently required to consolidate these findings.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hipersensibilidade a Drogas / Hipersensibilidade Tipo de estudo: Evaluation_studies / Health_economic_evaluation Limite: Humans País/Região como assunto: Oceania Idioma: En Revista: Intern Med J Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hipersensibilidade a Drogas / Hipersensibilidade Tipo de estudo: Evaluation_studies / Health_economic_evaluation Limite: Humans País/Região como assunto: Oceania Idioma: En Revista: Intern Med J Ano de publicação: 2023 Tipo de documento: Article